Xspray Pharma
Xspray Pharma: Shaping up to an exciting year (Redeye)

2019-03-19 07:30
In this update we look at the year ahead with the manufacturing and preparations to take HyNap-Dasa to market. We also update our view regarding the Sprycel, Nexavar and Tasigna market opportunities. We see a strong case in Xspray for the year going forward and reiterate our valuation range with a Base Case of SEK 135.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Xspray Pharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -